Publications by authors named "L Mallbris"
Article Synopsis
- Psoriasis is linked to higher cardiovascular risk, but how this connection works is not well understood, especially regarding systemic inflammation and skin disease severity.
- The study aims to determine if systemic inflammation acts as a mediator between the severity of psoriasis and cardiovascular disease using data from two patient cohorts in the U.S. and Sweden.
- Key outcomes analyzed include coronary artery health using advanced imaging and rates of hospitalization or death due to cardiovascular issues, with a focus on the roles of psoriasis severity and inflammation markers.
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis.
Eric L Simpson Marjolein de Bruin-Weller H Chih-Ho Hong Delphine Staumont-Sallé Andrew Blauvelt Lotus Mallbris
Dermatol Ther (Heidelb)
May 2024
Article Synopsis
- Atopic dermatitis (AD) is a skin condition that can be difficult to treat in certain body areas; this study focused on how lebrikizumab impacts AD severity across different regions.
- In two clinical trials, lebrikizumab was administered every two weeks, and patients showed significant improvement in the Eczema Area and Severity Index (EASI) after 16 weeks compared to those given a placebo.
- Results indicated that lebrikizumab led to rapid improvements in AD symptoms, with significant advancements observable as early as week 2, particularly benefiting all body regions and clinical signs measured.
Article Synopsis
- The study aims to compare the effectiveness of 11 biologic drugs for treating moderate-to-severe psoriasis using the "number needed to treat" (NNT) metric.
- Researchers analyzed data from 42 clinical trials to find NNT for various treatment responses at multiple weeks.
- Results indicated that brodalumab and ixekizumab had the lowest NNT for achieving psoriasis improvement at early weeks, while after 48/52 weeks, risankizumab and guselkumab showed similar efficacy.
Introduction: Psoriasis Area Severity Index (PASI) assessment is complex and time-consuming. A simpler assessment measure more sensitive to changes in symptom severity and predictive of patients' quality of life (Dermatology Life Quality Index, DLQI) is needed. This study aims to evaluate the Optimal Psoriasis Assessment Tool (OPAT) as an alternative to PASI.
View Article and Find Full Text PDFImportance: Psoriasis is a heterogeneous disease. Improved understanding of prognosis and long-term outcomes in new-onset psoriasis may improve care.
Objective: To describe the clinical course of psoriasis and identify possible indicators of long-term outcomes.